231 related articles for article (PubMed ID: 29044542)
1. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery.
Matsuo K; Johnson MS; Im DD; Ross MS; Bush SH; Yunokawa M; Blake EA; Takano T; Klobocista MM; Hasegawa K; Ueda Y; Shida M; Baba T; Satoh S; Yokoyama T; Machida H; Ikeda Y; Adachi S; Miyake TM; Iwasaki K; Yanai S; Takeuchi S; Nishimura M; Nagano T; Takekuma M; Shahzad MMK; Pejovic T; Omatsu K; Kelley JL; Ueland FR; Roman LD
J Surg Oncol; 2018 Mar; 117(3):488-496. PubMed ID: 29044542
[TBL] [Abstract][Full Text] [Related]
2. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
Makker V; Abu-Rustum NR; Alektiar KM; Aghajanian CA; Zhou Q; Iasonos A; Hensley ML
Gynecol Oncol; 2008 Nov; 111(2):249-54. PubMed ID: 18755503
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit.
Otsuki A; Watanabe Y; Nomura H; Futagami M; Yokoyama Y; Shibata K; Kamoi S; Arakawa A; Nishiyama H; Katsuta T; Kudaka W; Shimada M; Sato N; Kotera K; Katabuchi H; Yaegashi N
Int J Gynecol Cancer; 2015 Jan; 25(1):92-7. PubMed ID: 25347097
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy in uterine carcinosarcoma: Comparison of a doublet and a triplet chemotherapeutic regimen.
Maheshwari U; Rajappa SK; Talwar V; Goel V; Dash PK; Sharma M; Goyal P; Jain P; B Koyyala VP; Doval DC
Indian J Cancer; 2021; 58(2):179-184. PubMed ID: 33753600
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study.
Lorusso D; Martinelli F; Mancini M; Sarno I; Ditto A; Raspagliesi F
Int J Gynecol Cancer; 2014 Sep; 24(7):1256-61. PubMed ID: 25078338
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
Powell MA; Filiaci VL; Rose PG; Mannel RS; Hanjani P; Degeest K; Miller BE; Susumu N; Ueland FR
J Clin Oncol; 2010 Jun; 28(16):2727-31. PubMed ID: 20421537
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
Dandamudi RK; Aslam S; Walji N; El-Modir A; Fernando I
Anticancer Res; 2015 Sep; 35(9):4841-7. PubMed ID: 26254376
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
Matsuo K; Bond VK; Im DD; Rosenshein NB
Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
[TBL] [Abstract][Full Text] [Related]
10. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
Dickson EL; Vogel RI; Gehrig PA; Pierce S; Havrilesky L; Secord AA; Dottino J; Fader AN; Ricci S; Geller MA
Gynecol Oncol; 2015 Nov; 139(2):275-82. PubMed ID: 26348313
[TBL] [Abstract][Full Text] [Related]
11. Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years.
Matsuo K; Ross MS; Yunokawa M; Johnson MS; Machida H; Omatsu K; Klobocista MM; Im DD; Satoh S; Baba T; Ikeda Y; Bush SH; Hasegawa K; Blake EA; Takekuma M; Shida M; Nishimura M; Adachi S; Pejovic T; Takeuchi S; Yokoyama T; Ueda Y; Iwasaki K; Miyake TM; Yanai S; Nagano T; Takano T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
Surg Oncol; 2019 Jun; 29():25-32. PubMed ID: 31196490
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes in completely resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation.
Makker V; Kravetz SJ; Gallagher J; Orodel OP; Zhou Q; Iasonos A; DeLair D; Aghajanian C; Hensley ML
Int J Gynecol Cancer; 2013 Nov; 23(9):1635-41. PubMed ID: 24172099
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Galaal K; van der Heijden E; Godfrey K; Naik R; Kucukmetin A; Bryant A; Das N; Lopes AD
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD006812. PubMed ID: 23450572
[TBL] [Abstract][Full Text] [Related]
14. Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma.
McEachron J; Heyman T; Shanahan L; Tran V; Friedman M; Gorelick C; Economos K; Singhal PK; Lee YC; Kanis MJ
Int J Gynecol Cancer; 2020 Jul; 30(7):1012-1017. PubMed ID: 32447295
[TBL] [Abstract][Full Text] [Related]
15. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
[TBL] [Abstract][Full Text] [Related]
16. Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma.
Matsuo K; Ross MS; Yunokawa M; Johnson MS; Machida H; Omatsu K; Klobocista MM; Im DD; Satoh S; Baba T; Ikeda Y; Bush SH; Hasegawa K; Blake EA; Takekuma M; Shida M; Nishimura M; Adachi S; Pejovic T; Takeuchi S; Yokoyama T; Ueda Y; Iwasaki K; Miyake TM; Yanai S; Nagano T; Takano T; Shahzad MMK; Ueland FR; Kelley JL; Roman LD
Gynecol Oncol; 2017 Dec; 147(3):565-571. PubMed ID: 29056442
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study.
Takano T; Otsuki T; Tokunaga H; Toyoshima M; Utsunomiya H; Nagase S; Niikura H; Ito K; Yaegashi N; Yamada H; Tase T; Kagabu M; Shoji T; Sugiyama T; Sato N; Fujimoto T; Terada Y; Nakahara K; Kurachi H; Yokoyama Y; Mizunuma H; Soeda S; Nishiyama H; Matsumoto T; Sato S; Shimada M; Kigawa J
Int J Clin Oncol; 2014 Dec; 19(6):1052-8. PubMed ID: 24395448
[TBL] [Abstract][Full Text] [Related]
18. Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy.
Seagle BL; Kanis M; Kocherginsky M; Strauss JB; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):71-77. PubMed ID: 28317560
[TBL] [Abstract][Full Text] [Related]
19. Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.
Brackmann M; Stasenko M; Uppal S; Erba J; Reynolds RK; McLean K
BMC Cancer; 2018 Feb; 18(1):172. PubMed ID: 29426293
[TBL] [Abstract][Full Text] [Related]
20. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Wolfson AH; Brady MF; Rocereto T; Mannel RS; Lee YC; Futoran RJ; Cohn DE; Ioffe OB
Gynecol Oncol; 2007 Nov; 107(2):177-85. PubMed ID: 17822748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
